Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug ("NSAID") indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.
"We are pleased to partner with Dr. Reddy's Laboratories for the commercial launch of Ketorolac Tromethamine Tablets in the U.S. market," states Dhananjay Barot, Director, Senores Pharmaceuticals, Inc.
"Our constant dedication has contributed to expanding our product portfolio, and today we are a significant and reliable supplier of this product," states Swapnil Shah, Managing Director, Senores Group.
"We are excited about this launch, and pleased to partner with Senores to create affordable access to this product and expand our portfolio in the US market," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories.
The Toradol Tablets, 10 mg brand and generic had U.S. sales of approximately $16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA*.
Dr. Reddy's Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.
Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4351.10 as compared to the previous close of Rs. 4274.25. The total number of shares traded during the day was 20388 in over 2962 trades.
The stock hit an intraday high of Rs. 4375.95 and intraday low of 4252.25. The net turnover during the day was Rs. 88289561.00.